 five-year surviv cisplatin-bas chemotherapi single-ag melphalan patient advanc ovarian cancer optim debulk surgeri purpos studi surviv progression-fre surviv untreat patient advanc ovarian cancer single-ag melphalan patient underw optim debulk surgeri cm residu patient cisplatin-bas chemotherapi patient underw optim debulk surgeri signific increas surviv progression-fre surviv melphalan trial underw optim debulk surgeri pac-h pac trial underw optim debulk surgeri patient tumor trial signific differ median surviv median progression-fre surviv surviv progression-fre surviv patient melphalan pac-h pac optim debulk surgeri cisplatin-bas multiag chemotherapi small surviv advantag result similar gruppo interregional cooperativo oncologico ginecologia surviv curv ident subgroup chemotherapi regimen patient residu diseas cm onset chemotherapi cyclophosphamid cyclophosphamid adriamycin cyclophosphamid adriamycin cisplatin cyclophosphamid adriamycin hexamethylmelamin cisplatin cyclophosphamid low-dos cisplatin high-dos cisplatin carboplatin